[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636247":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":26,"locations":36,"responsibleParty":227,"collaborators":10,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":231,"sex":237,"minAge":238,"maxAge":10,"enrollmentInfo":239,"targetDuration":10,"studyType":242,"phases":10,"briefSummary":243,"conditions":244,"keywords":254,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},{"fullName":5,"class":6},"Groupe Francais De Pneumo-Cancerologie","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort A",null,"People with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort B","People with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program.",[16,20,23],{"name":17,"affiliation":18,"role":19},"Prof. Jean-Bernard Auliac","Service de Pneumologie - Centre Hospitalier Intercommunal de Créteil","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":22,"role":19},"Dr Thomas Pierret","Service de Pneumologie - Hôpital Louis Pradel GH Est-HCL",{"name":24,"affiliation":18,"role":25},"Prof. Christos Chouaïd","STUDY_CHAIR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Prof. Laurent Greillier","CONTACT","+33 4 73 98 39 86","a.boucheix@g-f-p-c.org",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Soizic Ferlandin","+33 6 63 22 47 89","soizic_ferlandin@yahoo.fr",[37,54,67,77,86,99,112,125,138,148,161,170,179,188,201,214],{"facility":38,"status":39,"city":40,"state":10,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CH du Pays d Aix - Service des Maladies Respiratoires","RECRUITING","Aix-en-Provence","13616","France","FR",{"type":45,"coordinates":46},"Point",[47,48],5.44973,43.5283,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":10,"phoneExt":10,"email":53},"Solène CHALEAT","schaleat@ch-aix.fr",{"facility":55,"status":39,"city":56,"state":10,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"APHP Hôpital Avicennes","Bobigny","93000",{"type":45,"coordinates":59},[60,61],2.45012,48.90982,{"lat":61,"lon":60},[64],{"name":65,"role":29,"phone":10,"phoneExt":10,"email":66},"Boris DUCHEMANN","boris.duchemann@aphp.fr",{"facility":68,"status":69,"city":70,"state":10,"zip":71,"country":42,"countryCode":43,"cosmosGeoPoint":72,"geoPoint":76,"contacts":10},"Hôpital Louis Pradel","ACTIVE_NOT_RECRUITING","Bron","69500",{"type":45,"coordinates":73},[74,75],4.91303,45.73865,{"lat":75,"lon":74},{"facility":78,"status":69,"city":79,"state":10,"zip":80,"country":42,"countryCode":43,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"Pneumologie Centre François Baclesse","Caen","14000",{"type":45,"coordinates":82},[83,84],-0.35912,49.18585,{"lat":84,"lon":83},{"facility":87,"status":39,"city":88,"state":10,"zip":89,"country":42,"countryCode":43,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Pneumologie Centre Hospitalier Intercommunal de Créteil","Créteil","94010",{"type":45,"coordinates":91},[92,93],2.46569,48.79266,{"lat":93,"lon":92},[96],{"name":97,"role":29,"phone":10,"phoneExt":10,"email":98},"Jean-Bernard AULIAC","jean-bernard.auliac@chicreteil.fr",{"facility":100,"status":39,"city":101,"state":10,"zip":102,"country":42,"countryCode":43,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Hôpital A. Mignot","Le Chesnay","78157",{"type":45,"coordinates":104},[105,106],2.12213,48.8222,{"lat":106,"lon":105},[109],{"name":110,"role":29,"phone":10,"phoneExt":10,"email":111},"Cécile DUJON","Cdujon@ght78sud.fr",{"facility":113,"status":39,"city":114,"state":10,"zip":115,"country":42,"countryCode":43,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Pneumologie Hôpital Calmette","Lille","59000",{"type":45,"coordinates":117},[118,119],3.05512,50.63391,{"lat":119,"lon":118},[122],{"name":123,"role":29,"phone":10,"phoneExt":10,"email":124},"Alexis CORTOT","elexis.cortot@chru-lille.fr",{"facility":126,"status":39,"city":127,"state":10,"zip":128,"country":42,"countryCode":43,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Pneumologie Hôpital privé Jean Mermoz","Lyon","69085",{"type":45,"coordinates":130},[131,132],4.84789,45.74906,{"lat":132,"lon":131},[135],{"name":136,"role":29,"phone":10,"phoneExt":10,"email":137},"Pierre BOMBARON","p.bombaron@orange.fr",{"facility":139,"status":39,"city":127,"state":10,"zip":140,"country":42,"countryCode":43,"cosmosGeoPoint":141,"geoPoint":143,"contacts":144},"Centre Léon Bérard","69373",{"type":45,"coordinates":142},[131,132],{"lat":132,"lon":131},[145],{"name":146,"role":29,"phone":10,"phoneExt":10,"email":147},"Romane GILLE","romane.gille@lyon.unicancer.fr",{"facility":149,"status":39,"city":150,"state":10,"zip":151,"country":42,"countryCode":43,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Hôpital Nord","Marseille","13915",{"type":45,"coordinates":153},[154,155],5.38107,43.29695,{"lat":155,"lon":154},[158],{"name":159,"role":29,"phone":10,"phoneExt":10,"email":160},"Laurent GREILLIER","laurent.GREILLIER@ap-hm.fr",{"facility":162,"status":69,"city":163,"state":10,"zip":164,"country":42,"countryCode":43,"cosmosGeoPoint":165,"geoPoint":169,"contacts":10},"CHRU de Nancy","Nancy","54000",{"type":45,"coordinates":166},[167,168],6.18496,48.68439,{"lat":168,"lon":167},{"facility":171,"status":69,"city":172,"state":10,"zip":173,"country":42,"countryCode":43,"cosmosGeoPoint":174,"geoPoint":178,"contacts":10},"Centre Antoine Lacassagne","Nice","06149",{"type":45,"coordinates":175},[176,177],7.26608,43.70313,{"lat":177,"lon":176},{"facility":180,"status":69,"city":181,"state":10,"zip":182,"country":42,"countryCode":43,"cosmosGeoPoint":183,"geoPoint":187,"contacts":10},"Institut Curie","Paris","75005",{"type":45,"coordinates":184},[185,186],2.3488,48.85341,{"lat":186,"lon":185},{"facility":189,"status":39,"city":190,"state":10,"zip":191,"country":42,"countryCode":43,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"CH de la Région d'Annecy - Service de Pneumologie","Pringy","74374",{"type":45,"coordinates":193},[194,195],6.12608,45.94622,{"lat":195,"lon":194},[198],{"name":199,"role":29,"phone":10,"phoneExt":10,"email":200},"Valérie PAULUS","vpaulus@ch-annecygenevois.fr",{"facility":202,"status":39,"city":203,"state":10,"zip":204,"country":42,"countryCode":43,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Pneumologie CHU St Etienne","Saint-Etienne","42270",{"type":45,"coordinates":206},[207,208],4.39,45.43389,{"lat":208,"lon":207},[211],{"name":212,"role":29,"phone":10,"phoneExt":10,"email":213},"Sophie BAYLE-BLEUEZ","sophie.bayle@chu-st-etienne.fr",{"facility":215,"status":39,"city":216,"state":10,"zip":217,"country":42,"countryCode":43,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"CHU La Réunion Site Sud","Saint-Pierre","97410",{"type":45,"coordinates":219},[220,221],5.40682,43.29282,{"lat":221,"lon":220},[224],{"name":225,"role":29,"phone":10,"phoneExt":10,"email":226},"Aurélie KIENLEN","aurelie.kienlen@chr-reunion.fr",{"type":228,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100636247","observational-multicenter-study-in-patients-receiving-chemotherapy-and-amivantamab-for-metastatic-non-small-cell-lung-cancer-100636247",false,"NCT07563205","Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer","Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program","OMAE","Inclusion Criteria:\n\n* Patient over 18 years old\n* Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.\n* Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.\n* Patient covered by the French National Health Insurance system or by an approved third-party payer\n* Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)\n\nExclusion Criteria:\n\n* Patient placed under legal guardianship or subject to a protective legal measure\n* Patient who explicitly refuses the collection or use of their personal data for research purposes\n* Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator","ALL","18 Years",{"count":240,"type":241},100,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have certain EGFR gene mutations.\n\nThe study includes two groups of people:\n\n* Group A: people with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program.\n* Group B: people with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program.\n\nThe main question the study wants to answer is:\n\nHow long can the combination of amivantamab and chemotherapy keep the cancer from coming back or getting worse in these two groups of people?\n\nPeople already receiving amivantamab and chemotherapy for NSCLC through an early access program may be included. They will continue to be followed by their usual oncologist as part of their normal medical care. The study will simply collect their medical information from March 21, 2024 to October 21, 2025.\n\nNo extra tests or procedures are required. This is an observational study, carried out by the GFPC and partner centers in France.",[245,246,247,248,249,250,251,252,253],"Non-Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer NSCLC","Non Small Cell Lung Carcinoma","NSCLC","EGFR","EGFR Exon 20 Insertion Mutation","EGFR Exon 19 Deletion Mutation","EGFR Exon 21 Mutation",[255,256,257,258,259,260,249],"Lung Cancer","Non Small Cell lung cancer","Metastatic lung cancer","EGFR Exon 20","EGFR Exon 19","EGFR Exon 21","2026-04-24",{"date":263,"type":264},"2026-05-01","ACTUAL",{"date":266,"type":264},"2025-11-19",{"date":268,"type":241},"2027-11-19",{"name":270,"class":6},"GFPC Investigation",16]